BMI for Weight Loss Injections: UK Eligibility

BMI for weight loss injections is a key eligibility factor in the UK, but it is rarely the only consideration. Injectable weight management medicines such as semaglutide (Wegovy) and tirzepatide (Mounjaro) are subject to specific NICE criteria, including BMI thresholds, comorbidity requirements and ethnicity-adjusted cut-offs. Whether you are exploring NHS or private routes, understanding how BMI interacts with other clinical factors can help you have a more informed conversation with a clinician. This article explains the thresholds, available treatments, assessment process, safety considerations and how to take the next step.

What BMI do you need to qualify for weight loss injections in the UK?

A BMI of 30 kg/m² or above is generally required, though NICE criteria differ by medicine and lower thresholds apply for certain ethnic groups and those with weight-related comorbidities.

In the UK, the BMI threshold for injectable weight management medicines is generally 30 kg/m² or above, though this can be lower for certain ethnic groups and for people with weight-related health conditions.^[1][2] NICE technology appraisals set out specific eligibility criteria for each medicine, and these criteria differ between treatments.

For semaglutide (Wegovy), NICE guidance specifies a BMI of at least 35 kg/m² alongside at least one weight-related comorbidity, or a BMI of 30 to 34.9 kg/m² in certain circumstances. Lower BMI thresholds apply for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean family background, in line with NICE and NHS guidance on ethnicity-specific BMI adjustments.^[4][1] For tirzepatide (Mounjaro), NICE has issued separate guidance with its own BMI and comorbidity criteria.

BMI is not the only factor considered. Clinicians also assess overall health, existing medical conditions, previous attempts at weight management, and whether the treatment is appropriate for the individual. Eligibility below BMI 30 is medicine-specific and typically restricted to defined circumstances within each NICE technology appraisal or the relevant UK Summary of Product Characteristics (SmPC); it is not a general rule. A person with a BMI above the threshold but without the required comorbidities may not qualify, and eligibility is always determined by a clinician rather than by self-assessment.

BMI thresholds also differ between NHS and private pathways. NHS access is governed by NICE guidance and local Integrated Care Board (ICB) commissioning decisions, which means availability can vary by region. Private prescribing must align with the licensed indications in each medicine's UK SmPC, or be clearly justified if off-label, and remains at the prescriber's clinical discretion. Always confirm eligibility with a qualified clinician rather than self-assessing on BMI alone.

Which weight loss injections are available on the NHS and privately?

Semaglutide (Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda) are all MHRA-authorised; NHS access depends on NICE guidance and local ICB commissioning, while all three are available privately following clinical assessment.

Several injectable medicines are currently authorised by the MHRA for chronic weight management in the UK, with the main options being semaglutide (Wegovy) and tirzepatide (Mounjaro), alongside the older liraglutide (Saxenda). Each belongs to a class of medicines that works on gut hormones to reduce appetite and slow gastric emptying, helping people eat less and feel fuller for longer.

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist administered as a once-weekly subcutaneous injection. It is available in dose strengths up to 2.4 mg weekly, with a higher 7.2 mg strength also authorised by the MHRA. NICE has recommended Wegovy for use within a specialist weight management service on the NHS, subject to ICB commissioning decisions.^[2][3]

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, also given as a once-weekly subcutaneous injection.^[9][11] Tirzepatide holds a UK licence for both type 2 diabetes and chronic weight management.^[10][9] NICE has appraised Mounjaro for weight management, and NHS availability depends on local ICB decisions.

Saxenda (liraglutide) is a daily injectable GLP-1 receptor agonist that has been available for longer.^[19][20] It is less commonly initiated now given the availability of newer once-weekly options, though it remains licensed and available.

All three are available through private providers, subject to a clinical assessment confirming eligibility. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a clinician may consider one of these options if it is clinically appropriate. NHS access remains subject to local commissioning, and not all ICBs have implemented NICE guidance at the same pace.

What health checks and assessments will a clinician carry out?

A clinician will assess BMI, medical history, current medicines, blood pressure, relevant blood tests, mental health, pregnancy status and lifestyle factors before prescribing any injectable weight management medicine.

Before prescribing any injectable weight management medicine, a clinician will carry out a structured assessment to confirm eligibility, identify any contraindications, and establish a safe starting point for treatment. This assessment is a clinical requirement, not a formality, and its thoroughness is a marker of a responsible service.

A typical assessment will include:

• BMI calculation, using current height and weight, with adjustment for ethnicity where relevant

• Medical history review, covering conditions such as type 2 diabetes, cardiovascular disease, kidney disease, liver disease, thyroid disorders and a personal or family history of pancreatitis

• Current medicines review, to check for interactions and to assess whether any existing treatments (for example, insulin or sulfonylureas in people with diabetes) may need adjustment

• Blood pressure measurement, as hypertension is both a common comorbidity and a factor in treatment decisions

• Blood tests, which may include HbA1c, liver function, kidney function and lipid profile, depending on the clinical picture

• Mental health and eating behaviour screening, since injectable weight management medicines are not appropriate for people with certain eating disorders

Clinicians will also discuss lifestyle factors, including diet and physical activity, because these medicines are intended to be used alongside behavioural changes rather than as a standalone intervention.

Pregnancy status is always assessed. The UK SmPCs for these medicines advise that they should not be used during pregnancy, and women who become pregnant during treatment should stop the medicine and contact their prescriber or GP promptly. Women of childbearing potential are advised to use effective contraception. For tirzepatide specifically, the UK SmPC (section 4.5) advises using an additional non-oral contraceptive method for four weeks after starting and for four weeks after each dose increase, because oral contraceptive absorption may be affected during dose escalation.

Regarding breastfeeding, the UK SmPCs for these medicines advise that they should not be used during breastfeeding; patients should discuss this with their clinician, as the precise wording varies between products.^[8][11]

Are there any side effects or safety considerations to be aware of?

The most common side effects are gastrointestinal, including nausea and vomiting; more serious risks include pancreatitis, gallbladder disease and hypoglycaemia, particularly in people taking insulin or sulfonylureas.

Injectable weight management medicines are generally well tolerated, but they do carry a recognised side effect profile that patients should understand before starting treatment. The most commonly reported effects are gastrointestinal and include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These effects are most pronounced during dose escalation and typically improve as the body adjusts to the medicine. Starting at a low dose and increasing gradually, as set out in each medicine's dosing schedule, helps to minimise these symptoms.

Injection-site reactions such as redness, itching or discomfort at the injection site are also commonly reported and are usually mild and transient.

If vomiting or diarrhoea is severe or prolonged, there is a risk of dehydration, which in some cases can affect kidney function. Patients should maintain adequate fluid intake during episodes of gastrointestinal upset and seek medical advice if symptoms are persistent or they are unable to keep fluids down.

More serious but less common considerations include:

• Pancreatitis: acute pancreatitis has been reported with GLP-1 receptor agonists, including post-marketing reports of necrotising pancreatitis and cases with a fatal outcome.^[14] Patients should seek prompt medical attention if they develop severe and persistent abdominal pain, particularly if it radiates to the back

• Gallbladder disease: gallstones and cholecystitis have been reported, particularly with rapid weight loss

• Heart rate: a modest increase in resting heart rate has been observed with some medicines in this class^[18]

• Diabetic eye disease: in people with pre-existing pre-proliferative or proliferative diabetic retinopathy, rapid improvement in blood glucose control may be associated with transient worsening of retinopathy; this should be discussed with a clinician before starting treatment^[17][18]

• Hypoglycaemia: this is a risk primarily in people also taking insulin or sulfonylureas

Patients should contact their GP if they experience persistent or worsening side effects, and call NHS 111 for urgent advice if they are concerned but the situation is not immediately life-threatening. A 999 call or attendance at A&E is appropriate only for a genuine emergency. Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

How to find out if you are eligible and what to do next

Speak with a qualified clinician, either your GP for NHS referral or a regulated private provider, who can assess your full medical history rather than BMI alone to determine eligibility.

The most reliable way to find out whether you are eligible for injectable weight management treatment is to speak with a qualified clinician who can assess your full medical history, not simply check your BMI against a threshold. Eligibility depends on a combination of factors including BMI, the presence of weight-related health conditions, current medicines, and overall suitability for the specific treatment being considered.

If you are interested in NHS access, your first step is to speak with your GP. They can assess whether you meet the criteria set out in relevant NICE guidance and refer you to a specialist weight management service if appropriate. NHS availability varies by area, as local ICBs make commissioning decisions independently, and waiting times for specialist services can be lengthy in some regions.

For those considering a private route, it is important to choose a provider that conducts a thorough clinical assessment rather than simply processing an order. Regulatory oversight varies across the four UK nations:

• Pharmacies: the General Pharmaceutical Council (GPhC) registers and inspects pharmacies in Great Britain; its register can be checked at pharmacyregulation.org. In Northern Ireland, pharmacies are regulated by the Pharmaceutical Society of Northern Ireland (PSNI).

• Service providers: in England, services can be checked with the Care Quality Commission (CQC); in Wales, with Healthcare Inspectorate Wales (HIW); in Scotland, with Healthcare Improvement Scotland (HIS); and in Northern Ireland, with the Regulation and Quality Improvement Authority (RQIA).

• Prescribers: doctors should be registered with the General Medical Council, whose register is searchable at gmc-uk.org.

Whichever route you choose, be prepared to engage with ongoing monitoring. These medicines require regular review to assess response, manage side effects, and adjust treatment as needed. Weight management is a long-term process, and injectable medicines are most effective when combined with sustained changes to diet and physical activity. If at any point you feel unwell or have concerns about your treatment, contact your prescribing clinician or GP in the first instance.

Scientific References

1. Overweight and obesity management – A guide for prescribing medicines to manage overweight and obesity in adults (NG246).
2. Semaglutide for managing overweight and obesity – Recommendations (TA875).
3. Overview – Semaglutide for managing overweight and obesity (TA875).
4. NG246 Appendix A1: Summary of evidence from surveillance – ethnicity-specific BMI cut-off points.
5. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
6. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
7. Wegovy 7.2 mg solution for injection in pre-filled pen – Summary of Product Characteristics.
8. Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics.
9. Tirzepatide – BNF/NICE.
10. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
11. Mounjaro EPAR product information (tirzepatide).
12. Women on 'skinny jabs' must use effective contraception – MHRA guidance.
13. Tirzepatide interactions – BNF/NICE.
14. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
15. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications. Therapeutic Advances in Endocrinology and Metabolism.
16. Acute biliary pancreatitis after semaglutide dose escalation in an adolescent with obesity and cholelithiasis. Frontiers in Pediatrics.
17. NG242 Diabetic retinopathy: management and monitoring – effectiveness of intensive treatments to lower blood glucose levels.
18. GLP-1 receptor agonists and serious adverse events: evidence, uncertainty and clinical implications. Journal of Internal Medicine.
19. Liraglutide – BNF/NICE.
20. Liraglutide: a medicine to treat type 2 diabetes or obesity – NHS.

Frequently Asked Questions